When is prophylaxis for hereditary angioedema necessary?

Area of Science:

• Immunology
• Genetics
• Pharmacology

Background:

• Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent swelling attacks.
• Androgens are a traditional prophylaxis for HAE but have significant adverse events.
• Newer agents, including C1 esterase inhibitor protein (C1-INH), are emerging as alternatives.

Purpose of the Study:

• To determine the appropriate timing and indications for considering C1-INH prophylaxis for HAE.
• To evaluate C1-INH as an alternative to androgen therapy, considering its efficacy and safety profile.

Main Methods:

• A comprehensive literature review of HAE therapy was conducted.
• Guideline reviews and expert panel discussions informed the decision-making process.
• Articles on HAE treatment published in peer-reviewed literature were selected for analysis.

Main Results:

• C1-INH has demonstrated efficacy for HAE prophylaxis, with a favorable half-life for this use.
• The short half-lives of other agents (ecallantide, icatibant, recombinant human C1-INH) limit their prophylactic utility.
• Specific patient criteria, including attack frequency, severity, quality of life, and previous severe events, indicate the need for prophylaxis.

Conclusions:

• C1-INH prophylaxis should be considered for HAE patients with frequent or severe attacks, laryngeal involvement, or significant quality of life impairment.
• Patients experiencing androgen intolerance, adverse reactions, or failure of androgen therapy are prime candidates for C1-INH prophylaxis.
• Prophylaxis decisions should be individualized based on patient-specific factors and treatment history.